FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions
MiniMed Receives FDA Clearance For Its First Tubeless Insulin Pump, The MiniMed Fit; Phased Rollout To Begin In Spring 2027
Barclays Maintains Equal-Weight on Minimed Group, Lowers Price Target to $20
MiniMed to Participate in Upcoming Investor Conferences
MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results
MiniMed Appoints Dr. David Segal as Chief Medical Officer
MiniMed Names Kevin E. Lofton Board Chair, Effective Separation From Medtronic
Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer
Medtronic’s Previously Announced MiniMed Share Exchange Offer Oversubscribed As Company Moves To Exchange Remaining 252,813,348 Shares; 4.5939 Shares Of MiniMed Common Stock Will Be Exchanged For Each Medtronic Ordinary Share Accepted In The Exchange Offer
Jefferies Initiates Coverage On Minimed Group with Hold Rating, Announces Price Target of $22
Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $28
Barclays Initiates Coverage On Minimed Group with Equal-Weight Rating, Announces Price Target of $22
Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes
MiniMed Study Links More Alert Responses To Better Diabetes Control
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
Truist Securities Initiates Coverage On Minimed Group with Buy Rating, Announces Price Target of $29
MiniMed Group, Inc. (MMED) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MiniMed (MMED): Nine Analysts Raised Targets, But Cash Flow Still Has a Catch
MiniMed Files Form S-4 with SEC For Medtronic Exchange Offer Covering 225M Shares of MiniMed Common Stock
MiniMed (MMED) Q1 2027 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.